PDL BIOPHARMA, INC. Uncategorized Contracts & Agreements
35 Contracts & Agreements
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 29, 2021)
- Asset Transfer Agreement dated as of August 11, 2020 between Defined Diagnostics, LLC (F/K/A Wellstat Diagnostics LLC) and the (Filed With SEC on November 13, 2020)
- Tax Matters Agreement, dated as of September 30, 2020, between PDL BioPharma, Inc. and LENSAR, Inc (Filed With SEC on October 2, 2020)
- Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 11, 2020)
- Offer Letter between the Company and Ed Imbrogno (Filed With SEC on June 24, 2019)
- Offer Letter between the Company and Dominique Monnet, executed August 31, 2017 (Filed With SEC on September 11, 2017)
- Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked * * * and has been filed separately with the Securities and Exchange Commission pursuant... (Filed With SEC on August 4, 2016)
- 932 Southwood BoulevardIncline Village, NV 89451Phone: (775) 832-8500Fax: (775) 832-8502 (Filed With SEC on August 5, 2015)
- 932 Southwood BoulevardIncline Village, NV89451Phone:(775) 832-8500Fax ###-###-#### (Filed With SEC on February 23, 2012)
- Offer Letter between the Company and Danny Hart, dated January 11, 2010 (Filed With SEC on April 18, 2011)
- PATENTLICENSE AGREEMENT between PROTEINDESIGN LABS, INC. and MEDIMMUNE,INC. (Filed With SEC on January 24, 2011)
- - 1 - (Filed With SEC on November 9, 2010)
- AMENDED AND RESTATED PATENT LICENSING MASTER AGREEMENT (QUEEN PATENTS) (Filed With SEC on November 9, 2010)
- PDL BIOPHARMA, INC. 2005 EQUITYINCENTIVE PLAN (AMENDED AND RESTATEDEFFECTIVE JUNE 4, 2009) PDL BIOPHARMA, INC. (Filed With SEC on July 31, 2009)
- CONFIDENTIAL PROVISIONS MARKED (Filed With SEC on March 2, 2009)
- CONFIDENTIAL PROVISIONS MARKED (Filed With SEC on March 2, 2009)
- CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.26 (CONFIDENTIAL) AMENDMENT NO. 2 TO THE PATENT LICENSING MASTER AGREEMENT (Filed With SEC on March 2, 2009)
- AMENDMENT TO THE RIGHTS AGREEMENT (Filed With SEC on February 5, 2009)
- CONFIDENTIALPROVISIONS REDACTED (Filed With SEC on November 7, 2008)
- PDL BIOPHARMA, INC. RESTRICTEDSTOCK AGREEMENT (Filed With SEC on August 9, 2006)
- Exhibit 10.55 to Form 10-K CONFIDENTIAL PROVISIONS REDACTED (Filed With SEC on March 16, 2006)
- Exhibit 10.54 to Form 10-K CONFIDENTIAL PROVISIONS REDACTED (Filed With SEC on March 16, 2006)
- ASSETPURCHASE AGREEMENT CENTOCOR,INC (SELLER) ESPPHARMA, INC. (BUYER) January 31,2005 (Filed With SEC on March 25, 2005)
- ICOS CORPORATION MANUFACTURING AGREEMENT (Filed With SEC on March 16, 2005)
- AMENDEDAND RESTATED WORLDWIDE AGREEMENT (Filed With SEC on March 16, 2005)
- CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on November 5, 2004)
- Protein Design Labs, Inc. Retiree Health Care Plan Effective June 1, 2003 (Filed With SEC on March 8, 2004)
- CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.49 (CONFIDENTIAL) (Filed With SEC on March 8, 2004)
- CONFIDENTIAL PROVISIONS MARKED EXHIBIT 10.48 (CONFIDENTIAL) (Filed With SEC on March 8, 2004)
- AMENDMENT NO. 1 TO THE HERCEPTINLICENSE AGREEMENT (Filed With SEC on March 8, 2004)
- EXHIBIT10.46 (CONFIDENTIAL) (Filed With SEC on March 8, 2004)
- CONFIDENTIALPROVISIONS MARKED (Filed With SEC on March 8, 2004)
- Financial statements of businesses acquired (Filed With SEC on April 18, 2003)
- Financial statements of businesses acquired (Filed With SEC on April 18, 2003)
- Financial statements of businesses acquired (Filed With SEC on April 18, 2003)
